Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9666232 | 0.90 | MRGPRX4 (0.47) | SMN1; SMN2ALDH1A1HTTTDP1HSP90AA1 | |
| SCHEMBL28816972 | 0.87 | HTT (0.53) | SMN1; SMN2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL18749651 | 0.87 | HIF1A (0.44) | ALDH1A1HTTPTGDR2MAPTNPSR1 | |
| SCHEMBL29787364 | 0.87 | RXRA (0.47) | ALDH1A1HTTTDP1PTGDR2NPSR1 | |
| SCHEMBL8848536 | 0.87 | RXRA (0.47) | ALDH1A1HTTTDP1PTGDR2NPSR1 | |
| SCHEMBL1256265 | 0.86 | MEN1 (0.49) | SMN1; SMN2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL3499125 | 0.86 | MEN1 (0.48) | SMN1; SMN2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL7535610 | 0.84 | HIF1A (0.62) | SMN1; SMN2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL42033 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL8619665 | 0.84 | HIF1A (0.62) | SMN1; SMN2MEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101849000-B | Reductase, gene thereof and method of using the same | SUMITOMO CO LTD | 2013-07-03 | — | — | CN | disclosed |
| CN-101679967-B | Reductase, gene thereof, and method for using same | SUMITOMO CHEMICAL CO | 2013-06-12 | — | — | CN | disclosed |
| US-8252563-B2 | Reductase, gene thereof and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8192967-B2 | Reductase, gene thereof and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-06-05 | — | — | US | disclosed |
| CN-101849000-A | Reductase, gene thereof and method of using the same | SUMITOMO CHEMICAL CO | 2010-09-29 | — | — | CN | disclosed |
| US-20100221799-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100112701-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| CN-101679967-A | Reductase, gene thereof, and method for using same | SUMITOMO CHEMICAL CO | 2010-03-24 | — | — | CN | disclosed |
| EP-2138579-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
| EP-2138578-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112701-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | BLVRB, ADH7, DHCR7 | SMN1; SMN2 4205/4885MEN1 4038/4885KMT2A 2407/4885 |
| US-20100221799-A1 | REDUCTASE, GENE THEREOF AND METHOD OF USING THE SAME | BLVRB, DHCR7, GRHPR | SMN1; SMN2 4008/4885MEN1 3911/4885KMT2A 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.